Actively Recruiting
A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis
Led by Imperial College London · Updated on 2025-07-09
54
Participants Needed
1
Research Sites
170 weeks
Total Duration
On this page
Sponsors
I
Imperial College London
Lead Sponsor
I
Imperial College Healthcare NHS Trust
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis. The investigators will compare the participants with bronchiectasis to a group of healthy participants. The main questions it aims to answer are: * Does viral infection with the common cold lead to an exacerbation in bronchiectasis? * Does the immune response differ to that of a healthy participant? Participants will attend for a screening visit to see if they are eligible. All participants who are eligible and have consented to take part will have baseline investigations done including blood tests and a bronchoscopy. They will be given a spray of a virus that causes the common cold into their nose. They will then be followed up over the next 6 weeks with some of the following procedures at each study visit; spirometry, nasosorption, nasal lavage, nasal brushing, blood test, sputum collection and a bronchoscopy. Participants will be asked to keep a daily record of their symptoms throughout the study.
CONDITIONS
Official Title
A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy volunteers aged 18 to 65 years
- Adults aged 18 to 65 years with confirmed bronchiectasis and severity index score of 0-8
- For participants with Pseudomonas colonisation, isolation of Pseudomonas aeruginosa in two or more cultures at least 3 months apart within 2 years
You will not qualify if you...
- Any medical condition that may affect the study as judged by the medical team
- Current smokers or those who quit within the last 12 months or with more than 5 pack years smoking history
- Presence of pre-existing neutralising antibodies to the rhinovirus strain used (RV-A16)
- Close contact with infants or elderly people at home or work
- Pregnancy or breastfeeding
- Bronchiectasis caused by cystic fibrosis, primary immunodeficiency, primary ciliary dyskinesia, or allergic bronchopulmonary aspergillosis
- Other significant chronic lung diseases affecting the study
- Lung function with FEV1 less than 50% predicted
- Recent antibiotics for exacerbations within 6 weeks or prophylactic antibiotics within 4 weeks
- Use of corticosteroids (inhaled, nasal, or systemic) within the last 4 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
St Mary's Hospital - Imperial Clinical Respiratory Research Unit (ICRRU)
London, United Kingdom, W2 1BL
Actively Recruiting
Research Team
C
Charlotte E Carter, MBChB
CONTACT
A
Aran Singanayagam, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here